Loading organizations...
Trinity Innovation Bioventure Singapore operates as a licensed biomed venture capital fund. It focuses on strategic innovation and value investment, leveraging its deep insights and experience within Asian markets. The fund aims to identify and cultivate promising companies that utilize emerging biotechnology to develop innovative therapeutics.
Established in 2018, Trinity Innovation Bioventure Singapore emerged from a recognized need for specialized investment within the burgeoning Asian biotechnology sector. The fund is managed by a team with extensive experience in both venture capital and the biotechnology industry, applying their expertise to identify high-potential opportunities.
Trinity Innovation Bioventure Singapore serves early-stage biotech companies, providing capital and strategic guidance. Its overarching vision is to foster the development of groundbreaking medical solutions, ultimately addressing significant global unmet medical needs through pioneering biotechnological advancements.
Trinity Innovation Fund has 4 tracked investments across 4 companies. The latest tracked deal is $41.0M Series A in Bowang Pharmaceutical in November 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2023 | Bowang Pharmaceutical | $41.0M Series A | — | Zhang Yi |
| Apr 25, 2023 | Adcentrx Therapeutics | $38.0M Series A | Tao Huang | Jeffrey Jonas, Delta Capital, F-Prime Capital |
| Aug 8, 2022 | Epigenic Therapeutics | $20.0M Pre-Series A | — | FountainBridge Capital, Kingray Capital, Michael Xue |
| Jun 14, 2021 | HiFiBiO | $75.0M Series D | Ryan Jeong | B Capital Group, Grand Mount, Hong Kong Science and Technology Parks Corporation, IDG Capital, Maison Capital, Sequoia Capital, Sherpa |
